Financial Milestone Fuels Pipeline Advancement

On March 27, 2025, MaaT Pharma announced the successful completion of a €13 million capital increase, supported by historical shareholders, extending the company’s cash runway into October 2025. This fresh funding enables MaaT Pharma to push forward pivotal European Medicines Agency (EMA) submissions and expand clinical activities for its lead microbiome-based asset, MaaT013, targeting acute graft-versus-host disease (aGvHD). The company also reported robust revenues from its Expanded Access Program (EAP), reflecting growing patient reach.

Continued Clinical Success in aGvHD

MaaT Pharma highlighted progress from its ongoing Phase 3 ARES trial evaluating MaaT013 in steroid- and ruxolitinib-refractory aGvHD patients. Recent data confirm a 62% gastrointestinal overall response rate at Day 28 and an expected 54% overall survival at one year, marking significant improvements over current treatment options. Earlier European EAP outcomes demonstrated sustained benefits and a positive safety profile in a fragile patient population with limited alternatives.

Strategic Focus on Hemato-Oncology and Commercial Partnerships

MaaT Pharma maintains leadership in microbiome therapeutics for hemato-oncology, actively preparing its Marketing Authorization Application dossier for EMA submission targeted for June 2025. Simultaneously, discussions continue with potential commercial partners to facilitate market access and patient availability, underscoring MaaT’s commitment to expanding its therapeutic impact beyond clinical trials.

Strengthening the Microbiome Therapy Landscape

MaaT Pharma’s milestone achievements exemplify the growing importance of microbiome modulation in treating immune-mediated diseases. Its innovative approach disrupts traditional treatment paradigms, offering targeted immune system restoration through complex ecosystem therapies.

Outlook: Robust Execution and Growth Prospects

With secured financing and promising clinical data, MaaT Pharma is poised for critical operational and strategic advances in 2025. The industry anticipates significant contributions to patient care as microbiome therapeutics move closer to mainstream adoption in hemato-oncology and transplantation medicine.